Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 680 participants.

Also called NCT07746882

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 680 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07746882
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07746882. Randomized; double masking; primary purpose treatment. Start 2026-08-15 (anticipated); primary completion 2028-08-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study on Anti-Thrombotic Regimens for Secondary Prevention in Ischemic Stroke Patients With Possible Benefit From Anticoagulation Therapy
Condition
Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
Rivaroxaban, or Edoxaban , or Apixaban , or Dabigatran
Intervention (Drug)
Aspirin
Lead sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine (class: other)

Record details

Record id
cardio:ct-nct07746882
Content hash
e220748d4958ede3e433ab9cda81157b67ef8ab74838d2eb11a7484eaef9c849